Attached files

file filename
8-K - 8-K - SPARTON CORPd722971d8k.htm

Exhibit 99.1

 

  Analyst Contact:    Mark Schlei
     Sparton Corporation
     Email: mschlei@sparton.com
     Office: (847) 762-5812
  Media Contact:    Mike Osborne
     Sparton Corporation
     Email: mosborne@sparton.com
     Office: (847) 762-5814
  Investor Contact:    John Nesbett/Jennifer Belodeau
     Institutional Marketing Services
     Email: jnesbett@institutionalms.com
     Office: (203) 972-9200

FOR IMMEDIATE RELEASE

Sparton Corporation Reports Fiscal 2014 Third Quarter Revenue Growth of 29% and Adjusted EBITDA Growth of 120% to $8.9 Million

SCHAUMBURG, IL.—May 6, 2014—Sparton Corporation (NYSE: SPA) today announced results for the third quarter of fiscal 2014 ended March 31, 2014. The Company reported third quarter sales of $83.9 million, or an increase of 29%, from $65.1 million for the third quarter of fiscal 2013. Operating income for the third quarter of fiscal 2014 was $6.3 million compared to $2.4 million in the third quarter of fiscal 2013. Net income for the third quarter of fiscal 2014 was $4.2 million or $0.42 per share, basic and diluted compared to net income of $1.5 million, or $0.15 per share, basic and diluted in the same quarter a year ago.

Consolidated Results for the Quarters and Nine Months Ended March 31, 2014 and 2013:

 

     For the Three Months Ended      For the Nine Months Ended  
     March 31,
2014
     March 31,
2013
     March 31,
2014
     March 31,
2013
 

Net sales

   $ 83,931       $ 65,148       $ 242,691       $ 183,203   

Gross profit

     16,426         10,125         43,597         30,220   

Operating income

     6,323         2,350         14,957         8,681   

Adjusted operating income

     6,471         2,350         15,401         9,247   

Net income

     4,246         1,536         10,016         7,834   

Adjusted net income

     4,347         1,536         10,315         6,145   

Income per share - basic

     0.42         0.15         0.99         0.77   

Adjusted income per share - basic

     0.43         0.15         1.02         0.60   

Income per share - diluted

     0.42         0.15         0.99         0.77   

Adjusted income per share - diluted

     0.43         0.15         1.02         0.60   

Adjusted EBITDA

     8,865         4,020         21,772         12,558   


Cary Wood, President & CEO, commented, “We are pleased with our continued success in this fiscal year. After nine months, we have seen a 32% increase in revenue and a 73% adjusted EBITDA improvement as compared to the same prior year period. As we enter the last quarter of the fiscal year, legacy revenue after three quarters is up 9% from the prior year with strong growth in our DSS segment as domestic and foreign sonobuoy sales are ahead of last fiscal year’s pace, and in Complex Systems where we have seen increased demand from a number of key customers. The Medical segment’s year-to-date results have held steady as programs in-sourced at two customers have been offset with increased demand at a number of customers. The remaining 23% revenue growth was realized through the acquisitions of Onyx, Creonix, Aydin, Beckwood Services and, most recently in the quarter, Aubrey Group. The results continue to reflect the successful execution of our strategic growth plan, in particular our new business development process and our approach to complementary acquisitions.”

Third Quarter Financial Highlights

 

    Quarterly revenue grew 29% to $84 million as compared to the same quarter of the prior year.

 

    Organic growth, net of acquisitions, was 11% from the same quarter of the prior year.

 

    Adjusted EBITDA grew 120% in the quarter and 73% YTD as compared to the prior year periods.

 

    20 new business programs awarded with potential annualized sales of $6.1 million.

 

    Completed the acquisition of Aubrey Group, Inc.

Acquisition of Aubrey Group, Inc.

On March 17, 2014, the Company completed the acquisition of Aubrey Group, Inc. (“Aubrey”). The acquired business, which is part of the Medical segment and which is expected to add $8.0 million in annualized revenue, develops new products for Original Equipment Manufacturers (“OEM’”) in the Medical and Biotechnological markets. Inventors, entrepreneurs, and industry leading OEMs utilize Aubrey Group’s design and engineering teams to develop innovative solutions in a timely and cost effective manner.

“We are pleased to have acquired Aubrey Group, which will add an innovative product development offering to our portfolio, allowing us to provide enhanced services throughout the product lifecycle. A key component of our strategic vision at Sparton is to realize synergistic acquisition opportunities that add value to the core products and services in our portfolio. The Aubrey acquisition aligns tremendously with this vision. By combining our businesses, Sparton and Aubrey have the capability to enter into a new set of customer engagements that allow us to offer product design, product development, and product manufacturing more completely under one umbrella.”

Segment Results

Medical Device (“Medical”)

Included in the results for the Company’s Medical segment for the three months ended March 31, 2014 are net sales of approximately $0.3 million resulting from the acquisition of Aubrey. Excluding these sales, legacy Medical sales decreased approximately $2.2 million, or 6%, in the three months ended March 31, 2014 as compared with the prior year quarter. This comparative decrease primarily reflects a rebalancing of Fenwal program engagements with the Company beginning in the Company’s fiscal 2014 third quarter. The rebalancing of this customer’s programs is expected to negatively affect comparative sales to this customer by approximately $7 million in the Company’s fiscal 2014 fourth quarter and as much as $19 million in the Company’s fiscal 2015, substantially all of which will be realized during first half of that year.

Gross margin on Medical sales increased to 14.3% from 13.6% for the three months ended March 31, 2014 and 2013, respectively. This increase in margin percentage on Medical sales primarily reflects certain favorable product mix between the two periods.

Selling and administrative expenses relating to the Medical segment were $2.4 million for the three months ended March 31, 2014 compared to $2.2 million for the three months ended March 31, 2013, primarily reflecting incremental allocated expenses related to Onyx operations. Amortization of intangible assets was $0.5 million and $0.6 million for the three months ended March 31, 2014 and 2013, respectively. The Medical segment reported operating income of $2.5 million for each of the quarters ended March 31, 2014 and 2013 respectively.


Complex Systems (“CS”)

Included in the results for the Company’s Complex Systems segment for the three months ended March 31, 2014 are net sales of approximately $7.5 million resulting from the acquisitions of Creonix, LLC (“Creonix”) and Beckwood. Excluding these sales and an increase in intercompany sales of $1.0 million, CS sales to legacy external customers for the three months ended March 31, 2014 decreased $1.4 million, or 12%, as compared with the same quarter last year. This comparative decrease primarily reflects a sales delay in the current year quarter with one customer as it makes engineering design changes.

Gross margin on CS sales decreased to 10.6% for the three months ended March 31, 2014 compared to 11.5% for the three months ended March 31, 2013, primarily reflecting unfavorable product mix between the comparative periods.

Selling and administrative expenses relating to the CS segment were $1.1 million and $0.7 million for the three months ended March 31, 2014 and 2013, respectively, primarily due to the inclusion of operating expenses of Creonix and Beckwood. Amortization of intangible assets was $0.5 million for the three months ended March 31, 2014 due to the acquisitions of Creonix and Beckwood. CS reported operating income of $0.9 million for the quarter ended March 31, 2014 compared to operating income of $1.2 million in the prior year quarter. CS adjusted operating income was $1.0 million compared to operating income of $1.2 million in the prior year quarter.

Defense & Security Systems (“DSS”)

Included in the results for the Company’s Defense and Security Systems segment for the three months ended March 31, 2014 are net sales of approximately $4.1 million resulting from the acquisition of Aydin. Excluding the fiscal year 2014 incremental sales from the acquisition of Aydin, DSS legacy sales increased approximately $10.6 million, or 75%, in the three months ended March 31, 2014 as compared with the same quarter last year, reflecting increased sonobuoy sales to the U.S. Navy and foreign governments, as well as increased U.S Navy engineering sales.

Gross margin percentage on DSS sales increased to 29.8% for the three months ended March 31, 2014 compared to 20.4% for the three months ended March 31, 2013. Gross profit percentage was positively affected in the current year quarter by increased volume as well as favorable product mix as compared to the prior year quarter.

Selling and administrative expenses relating to the DSS segment were $2.2 million and $1.2 million for the three months ended March 31, 2014 and 2013, respectively, reflecting incremental expenses related to Aydin operations. The Company incurred $0.2 million and $0.3 million of internally funded research and development expenses in the three months ended March 31, 2014 and 2013, respectively. DSS reported operating income of $6.1 million for the quarter ended March 31, 2014 compared to operating income of $1.4 million in the prior year quarter. DSS adjusted operating income was $6.2 million compared to operating income of $1.4 million in the prior year quarter.

Liquidity and Capital Resources

As of March 31, 2014, the Company had $35.0 million borrowed and approximately $29 million available under its credit facility and had available cash and cash equivalents of $7.5 million. As of this date, the Company had received performance based payments under U.S. Navy contracts in excess of the funding of production to date under those contracts of $7.4 million.

Mr. Wood commented, “As we continue to see an increased number of opportunities, not only in number, but also in size, our remaining credit facility availability, coupled with the facility’s potential $35 million accordion feature, provides the Company with flexibility as we continue to pursue strategic acquisitions as part of our growth plan.”


Outlook

Cary Wood concluded, “The third quarter’s strong results build upon the success of the first two quarters of the fiscal year. As in prior years, we can experience revenue fluctuations within our reporting segments on a quarter-over-quarter basis. Our focus continues to be on managing the overall business, not only on the top line with revenue performance, but more importantly, the flow through of that revenue as adjusted EBITDA. As in prior quarters, we continue to execute our strategic growth plan to meet our growth expectations by focusing on new business development, internal product research and development, and compatible and complementary acquisitions. We are experiencing positive momentum from our new business development process with additional new business wins, increased inclusion of our inertial navigation sensors in key military projects and engineering wins from the sale of those products. The acquisition of synergistic entities remains a priority as evidenced by the closing of the Aubrey Group transaction that provides us with further product development capabilities and regional presence on the West Coast. As we look forward, we expect the fourth quarter will produce results at or above our current performance levels, adding to what has been an excellent fiscal year.”

Conference Call

Sparton will host a conference call with investors and analysts on May 7, 2014 at 10:00 a.m. CDT/11:00 a.m. EDT to discuss its fiscal year 2014 third quarter financial results, provide a general business update, and respond to investor questions. To participate, callers should dial (800) 706-9230. Participants should dial in at least 15 minutes prior to the start of the call. A Web presentation link is also available for the conference call: https://www.livemeeting.com/cc/gc_min_pro_usa/join?id=4RSNBJ&role=attend

Investors and financial analysts are invited to ask questions after the presentation is made. The presentation and a replay of the call will be available on Sparton’s Web site: http://www.sparton.com in the “Investor Relations” section for up to two years after the conference call.

Non-GAAP Financial Measures

In addition to reporting financial results in accordance with U.S. generally accepted accounting principles (“GAAP”), Sparton Corporation has provided non-GAAP financial measures as additional information for its operating results. These measures have not been prepared in accordance with GAAP and may be different from measures used by other companies. Whenever we use non-GAAP financial measures, we designate these measures, which exclude the effect of certain expenses and income, as “adjusted” and provide a reconciliation of non-GAAP financial measures to the most closely applicable GAAP financial measure. The non-GAAP financial measures eliminate or add certain items of expense and income from cost of goods sold, total operating expense, other income (expense) and provision for (benefit from) income taxes. Management believes that this presentation is helpful to investors in evaluating the current operational and financial performance of our business and facilitates comparisons to historical results of operations. Management discloses this information along with a reconciliation of the comparable GAAP amounts to provide access to the detail and nature of adjustments made to GAAP financial results. While some of these excluded items have been periodically reported in our statements of operations, including significant restructuring and impairment charges as well as certain gains on sales of assets, their occurrence in future periods depends on future business and economic factors, among other evaluation criteria, and the occurrence of such events and factors may frequently be beyond the control of management.

We exclude restructuring/impairment charges, gross profit effects of capitalized profit in inventory from acquisition and acquisition contingency settlement, and gain on sale of investment, the related tax effect of these items as well as unusual discrete tax benefits or expense because we believe that they are not related directly to the underlying performance of our fundamental business operations. We exclude these measures when reviewing financial results and for business planning. Although these events are reflected in our GAAP financials, these transactions may limit the comparability of our fundamental operations with prior and future periods.

Adjusted EBITDA represents earnings before interest, taxes, depreciation and amortization as adjusted for restructuring/impairment charges, gross profit effects of capitalized profit in inventory from acquisition and acquisition contingency settlement, and gain on sale of investment. The Company believes Adjusted EBITDA is commonly used by financial analysts and others in the industries in which the Company operates and, thus, provides useful information to investors. The Company does not intend, nor should the reader consider, Adjusted EBITDA an alternative to operating income, net income, net cash provided by operating activities or any other items calculated in accordance with GAAP. The Company’s definition of Adjusted EBITDA may not be comparable with Adjusted EBITDA as defined by other companies. Accordingly, the measurement has limitations depending on its use.


About Sparton Corporation

Sparton Corporation (NYSE:SPA), now in its 114th year, is a provider of complex and sophisticated electromechanical devices with capabilities that include concept development, industrial design, design and manufacturing engineering, production, distribution, and field service. The primary market classifications served are Navigation & Exploration, Defense & Security, Medical, and Complex Systems. Headquartered in Schaumburg, IL, Sparton currently has six manufacturing locations worldwide. Sparton’s Web site may be accessed at http://www.sparton.com.

Safe Harbor and Fair Disclosure Statement

Certain statements described in this press release are forward-looking statements within the scope of the Securities Act of 1933, as amended (the “Securities Act”), and the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements may be identified by the words “believe,” “expect,” “anticipate,” “project,” “plan,” “estimate,” “will” or “intend” and similar words or expressions. These forward-looking statements reflect Sparton’s current views with respect to future events and are based on currently available financial, economic and competitive data and its current business plans. Actual results could vary materially depending on risks and uncertainties that may affect Sparton’s operations, markets, prices and other factors. Important factors that could cause actual results to differ materially from those forward-looking statements include, but are not limited to, Sparton’s financial performance and the implementations and results of its ongoing strategic initiatives. For a more detailed discussion of these and other risk factors, see Part I, Item 1A, Risk Factors and Part II, Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, in Sparton’s Form 10-K for the year ended June 30, 2013, and its other filings with the Securities and Exchange Commission. Sparton undertakes no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.


SPARTON CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(Dollars in thousands, except share per share amounts)

 

     March 31,
2014
    June 30,
2013 (a)
 
Assets     

Current Assets:

    

Cash and cash equivalents

   $ 7,502      $ 6,085   

Accounts receivable, net of allowance for doubtful accounts of $108 and $61, respectively

     46,259        49,572   

Inventories and cost of contracts in progress, net

     51,466        46,334   

Deferred income taxes

     2,779        2,951   

Prepaid expenses and other current assets

     3,999        1,731   
  

 

 

   

 

 

 

Total current assets

     112,005        106,673   

Property, plant and equipment, net

     28,562        28,904   

Goodwill

     28,653        14,767   

Other intangible assets, net

     20,975        10,713   

Deferred income taxes—non-current

     102        4,075   

Other non-current assets

     2,924        790   
  

 

 

   

 

 

 

Total assets

   $ 193,221      $ 165,922   
  

 

 

   

 

 

 
Liabilities and Shareholders’ Equity     

Current Liabilities:

    

Current portion of long—term debt

   $ 1,737      $ 136   

Accounts payable

     20,425        19,596   

Accrued salaries and wages

     8,098        6,329   

Accrued health benefits

     1,433        1,793   

Performance based payments on customer contracts

     7,444        20,902   

Other accrued expenses

     10,188        6,733   
  

 

 

   

 

 

 

Total current liabilities

     49,325        55,489   

Pension liability—non-current portion

     233        274   

Long-term debt—non-current portion

     34,700        11,403   

Environmental remediation—non-current portion

     2,468        2,684   
  

 

 

   

 

 

 

Total liabilities

     86,726        69,850   

Commitments and contingencies

    

Shareholders’ Equity:

    

Preferred stock, no par value; 200,000 shares authorized, none issued

     —          —     

Common stock, $1.25 par value; 15,000,000 shares authorized, 10,126,275 and 10,095,716 shares issued and outstanding, respectively

     12,658        12,619   

Capital in excess of par value

     19,057        18,751   

Retained earnings

     75,973        65,957   

Accumulated other comprehensive loss

     (1,193     (1,255
  

 

 

   

 

 

 

Total shareholders’ equity

     106,495        96,072   
  

 

 

   

 

 

 

Total liabilities and shareholders’ equity

   $ 193,221      $ 165,922   
  

 

 

   

 

 

 

 

(a) Derived from the Company’s audited financial statements as of June 30, 2013.


SPARTON CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

(Dollars in thousands, except per share amounts)

 

     For the Three Months Ended     For the Nine Months Ended  
     March 31,
2014
    March 31,
2013
    March 31,
2014
    March 31,
2013
 

Net sales

   $ 83,931      $ 65,148      $ 242,691      $ 183,203   

Cost of goods sold

     67,505        55,023        199,094        152,983   
  

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit

     16,426        10,125        43,597        30,220   

Operating Expense:

        

Selling and administrative expenses

     8,807        6,803        25,139        19,650   

Internal research and development expenses

     213        341        1,004        889   

Amortization of intangible assets

     1,089        609        2,323        984   

Restructuring charges

     —          —          188        —     

Other operating (income) expenses

     (6     22        (14     16   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total operating expense, net

     10,103        7,775        28,640        21,539   
  

 

 

   

 

 

   

 

 

   

 

 

 

Operating income

     6,323        2,350        14,957        8,681   

Other income (expense):

        

Interest expense

     (187     (136     (547     (390

Interest income

     —          48        2        99   

Other, net

     124        106        461        275   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total other income (expense), net

     (63     18        (84     (16
  

 

 

   

 

 

   

 

 

   

 

 

 

Income before provision for income taxes

     6,260        2,368        14,873        8,665   

Provision for income taxes

     2,014        832        4,857        831   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income

   $ 4,246      $ 1,536      $ 10,016      $ 7,834   
  

 

 

   

 

 

   

 

 

   

 

 

 

Income per share of common stock:

        

Basic

   $ 0.42      $ 0.15      $ 0.99      $ 0.77   
  

 

 

   

 

 

   

 

 

   

 

 

 

Diluted

   $ 0.42      $ 0.15      $ 0.99      $ 0.77   
  

 

 

   

 

 

   

 

 

   

 

 

 

Weighted average shares of common stock outstanding:

        

Basic

     10,124,587        10,225,012        10,104,029        10,198,454   
  

 

 

   

 

 

   

 

 

   

 

 

 

Diluted

     10,150,253        10,250,700        10,127,811        10,225,191   
  

 

 

   

 

 

   

 

 

   

 

 

 


SPARTON CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

(Dollars in thousands)

 

     For the Nine Months Ended  
     March 31,
2014
    March 31,
2013
 

Cash Flows from Operating Activities:

    

Net income

   $ 10,016      $ 7,834   

Adjustments to reconcile net income to net cash provided by (used in) operating activities:

    

Depreciation and amortization

     5,910        3,036   

Deferred income tax expense

     545        844   

Stock-based compensation expense

     1,287        862   

Gross profit effect of capitalized profit in inventory from acquisition

     256        566   

Excess tax benefit of stock-based compensation

     (496     —     

Other

     66        75   

Changes in operating assets and liabilities:

    

Accounts receivable

     7,426        (1,359

Inventories and cost of contracts in progress

     3,497        (3,405

Prepaid expenses and other assets

     (1,196     (1,597

Performance based payments on customer contracts

     (13,458     (15,123

Accounts payable and accrued expenses

     1,358        1,960   
  

 

 

   

 

 

 

Net cash provided by (used in) operating activities

     15,211        (6,307

Cash Flows from Investing Activities:

    

Purchase of Onyx

     —          (45,438

Purchase of certain assets of Creonix

     105        —     

Purchase of certain assets and liabilities of Aydin Displays

     (15,502     —     

Purchase of Beckwood

     (15,346     —     

Purchase of Aubrey, net of acquired cash

     (4,817  

Purchases of property, plant and equipment

     (2,253     (2,971

Change in restricted cash

     —          (535

Proceeds from sale of property, plant and equipment

     69        275   
  

 

 

   

 

 

 

Net cash used in investing activities

     (37,744     (48,669

Cash Flows from Financing Activities:

    

Short-term bank borrowings, net

     —          22,400   

Borrowings of long-term debt

     53,000        —     

Repayment of long-term debt

     (28,108     (9,505

Payment of debt financing costs

     —          (445

Repurchase of stock

     (1,559     (234

Proceeds from the exercise of stock options

     121        168   

Excess tax benefit from stock-based compensation

     496        —     
  

 

 

   

 

 

 

Net cash provided by financing activities

     23,950        12,384   
  

 

 

   

 

 

 

Net increase (decrease) in cash and cash equivalents

     1,417        (42,592

Cash and cash equivalents at beginning of period

     6,085        46,950   
  

 

 

   

 

 

 

Cash and cash equivalents at end of period

   $ 7,502      $ 4,358   
  

 

 

   

 

 

 

Supplemental disclosure of cash flow information:

    

Cash paid for interest

   $ 465      $ 368   
  

 

 

   

 

 

 

Cash paid for income taxes

   $ 4,734      $ 1,337   
  

 

 

   

 

 

 


SPARTON CORPORATION AND SUBSIDIARIES

SELECT SEGMENT INFORMATION

(UNAUDITED)

(Dollars in thousands)

Net sales:

 

     For the Three Months Ended March 31,     For the Nine Months Ended March 31,  
SEGMENT    2014     2013     % Chg     2014     2013     % Chg  

Medical

   $ 37,215      $ 39,139        (4.9 )%    $ 123,539      $ 102,002        21.1

CS

     23,563        16,482        43.0        60,132        42,888        40.2   

DSS

     28,853        14,186        103.4        72,824        51,850        40.5   

Eliminations

     (5,700     (4,659     22.3        (13,804     (13,537     2.0   
  

 

 

   

 

 

     

 

 

   

 

 

   

Totals

   $ 83,931      $ 65,148        28.8      $ 242,691      $ 183,203        32.5   
  

 

 

   

 

 

     

 

 

   

 

 

   

Gross profit:

 

     For the Three Months Ended March 31,     For the Nine Months Ended March 31,  
SEGMENT    2014      GP %     2013      GP %     2014      GP %     2013      GP %  

Medical

   $ 5,332         14.3   $ 5,339         13.6   $ 19,134         15.5   $ 13,877         13.6

CS

     2,488         10.6        1,890         11.5        6,300         10.5        4,414         10.3   

DSS

     8,606         29.8        2,896         20.4        18,163         24.9        11,929         23.0   
  

 

 

      

 

 

      

 

 

      

 

 

    

Totals

   $ 16,426         19.6      $ 10,125         15.5      $ 43,597         18.0      $ 30,220         16.5   
  

 

 

      

 

 

      

 

 

      

 

 

    

Adjusted gross profit:

 

     For the Three Months Ended March 31,     For the Nine Months Ended March 31,  
SEGMENT    2014      GP %     2013      GP %     2014      GP %     2013      GP %  

Medical

   $ 5,332         14.3   $ 5,339         13.6   $ 19,134         15.5   $ 14,443         14.2

CS

     2,555         10.8        1,890         11.5        6,367         10.6        4,414         10.3   

DSS

     8,687         30.1        2,896         20.4        18,352         25.2        11,929         23.0   
  

 

 

      

 

 

      

 

 

      

 

 

    

Totals

   $ 16,574         19.7      $ 10,125         15.5      $ 43,853         18.1      $ 30,786         16.8   
  

 

 

      

 

 

      

 

 

      

 

 

    

Operating income:

 

     For the Three Months Ended March 31,     For the Nine Months Ended March 31,  
SEGMENT    2014     % of Sales     2013     % of Sales     2014     % of Sales     2013     % of Sales  

Medical

   $ 2,468        6.6   $ 2,483        6.3   $ 10,072        8.2   $ 6,908        6.8

CS

     946        4.0        1,203        7.3        2,850        4.7        2,366        5.5   

DSS

     6,112        21.2        1,351        9.5        10,986        15.1        7,506        14.5   

Other Unallocated

     (3,203       (2,687     —          (8,951       (8,099     —     
  

 

 

     

 

 

     

 

 

     

 

 

   

Totals

   $ 6,323        7.5      $ 2,350        3.6      $ 14,957        6.2      $ 8,681        4.7   
  

 

 

     

 

 

     

 

 

     

 

 

   

Adjusted operating income:

 

     For the Three Months Ended March 31,     For the Nine Months Ended March 31,  
SEGMENT    2014     % of Sales     2013     % of Sales     2014     % of Sales     2013     % of Sales  

Medical

   $ 2,468        6.6   $ 2,483        6.3   $ 10,072        8.2   $ 7,474        7.3

CS

     1,013        4.3        1,203        7.3        3,105        5.2        2,366        5.5   

DSS

     6,193        21.5        1,351        9.5        11,175        15.3        7,506        14.5   

Other Unallocated

     (3,203       (2,687     —          (8,951       (8,099     —     
  

 

 

     

 

 

     

 

 

     

 

 

   

Totals

   $ 6,471        7.7      $ 2,350        3.6      $ 15,401        6.3      $ 9,247        5.0   
  

 

 

     

 

 

     

 

 

     

 

 

   


SPARTON CORPORATION AND SUBSIDIARIES

RECONCILIATON OF NON-GAAP FINANCIAL MEASURES

(UNAUDITED)

(Dollars in thousands, except share data)

 

     For the Three Months Ended March 31, 2014     For the Three Months Ended March 31, 2013  
     GAAP     Non-GAAP
Adjustment
    Adjusted     GAAP     Non-GAAP
Adjustment
     Adjusted  

Net sales

   $ 83,931      $ —        $ 83,931      $ 65,148      $ —         $ 65,148   

Cost of goods sold

     67,505        (148     67,357        55,023        —           55,023   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

    

 

 

 

Gross profit

     16,426        148        16,574        10,125        —           10,125   

Operating Expense:

          

Selling and administrative expenses

     8,807        —          8,807        6,803        —           6,803   

Internal research and development expenses

     213        —          213        341        —           341   

Amortization of intangible assets

     1,089        —          1,089        609        —           609   

Restructuring charges

     —          —          —          —          —           —     

Other operating (income) expenses

     (6     —          (6     22        —           22   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

    

 

 

 

Total operating expense, net

     10,103        —          10,103        7,775        —           7,775   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

    

 

 

 

Operating income

     6,323        148        6,471        2,350        —           2,350   

Other income (expense):

          

Interest expense

     (187     —          (187     (136     —           (136

Interest income

     —          —          —          48        —           48   

Other, net

     124        —          124        106        —           106   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

    

 

 

 

Total other income (expense), net

     (63     —          (63     18        —           18   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

    

 

 

 

Income before provision for income taxes

     6,260        148        6,408        2,368        —           2,368   

Provision for income taxes

     2,014        47        2,061        832        —           832   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

    

 

 

 

Net income

   $ 4,246      $ 101      $ 4,347      $ 1,536      $ —         $ 1,536   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

    

 

 

 

Income per share of common stock:

          

Basic

   $ 0.42        $ 0.43      $ 0.15         $ 0.15   
  

 

 

     

 

 

   

 

 

      

 

 

 

Diluted

   $ 0.42        $ 0.43      $ 0.15         $ 0.15   
  

 

 

     

 

 

   

 

 

      

 

 

 

Weighted average shares of common stock outstanding:

          

Basic

     10,124,587          10,124,587        10,225,012           10,225,012   
  

 

 

     

 

 

   

 

 

      

 

 

 

Diluted

     10,150,253          10,150,253        10,250,700           10,250,700   
  

 

 

     

 

 

   

 

 

      

 

 

 


SPARTON CORPORATION AND SUBSIDIARIES

RECONCILIATON OF NON-GAAP FINANCIAL MEASURES

(UNAUDITED)

(Dollars in thousands, except share data)

 

     For the Nine Months Ended March 31, 2014     For the Nine Months Ended March 31, 2013  
     GAAP     Non-GAAP
Adjustment
    Adjusted     GAAP     Non-GAAP
Adjustment
    Adjusted  

Net sales

   $ 242,691      $      $ 242,691      $ 183,203      $      $ 183,203   

Cost of goods sold

     199,094        (256     198,838        152,983        (566     152,417   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit

     43,597        256        43,853        30,220        566        30,786   

Operating Expense:

            

Selling and administrative expenses

     25,139               25,139        19,650               19,650   

Internal research and development expenses

     1,004               1,004        889               889   

Amortization of intangible assets

     2,323               2,323        984               984   

Restructuring charges

     188        (188                            

Other operating (income) expenses

     (14            (14     16               16   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total operating expense, net

     28,640        (188     28,452        21,539               21,539   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Operating income

     14,957        444        15,401        8,681        566        9,247   

Other income (expense):

            

Interest expense

     (547            (547     (390            (390

Interest income

     2               2        99               99   

Other, net

     461               461        275               275   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total other income (expense), net

     (84            (84     (16            (16
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income before provision for income taxes

     14,873        444        15,317        8,665        566        9,231   

Provision for income taxes

     4,857        145        5,002        831        2,255        3,086   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income

   $ 10,016      $ 299      $ 10,315      $ 7,834      $ (1,689   $ 6,145   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income per share of common stock:

            

Basic

   $ 0.99        $ 1.02      $ 0.77        $ 0.60   
  

 

 

     

 

 

   

 

 

     

 

 

 

Diluted

   $ 0.99        $ 1.02      $ 0.77        $ 0.60   
  

 

 

     

 

 

   

 

 

     

 

 

 

Weighted average shares of common stock outstanding:

            

Basic

     10,104,029          10,104,029        10,198,454          10,198,454   
  

 

 

     

 

 

   

 

 

     

 

 

 

Diluted

     10,127,811          10,127,811        10,225,191          10,225,191   
  

 

 

     

 

 

   

 

 

     

 

 

 


SPARTON CORPORATION AND SUBSIDIARIES

RECONCILIATON OF NON-GAAP FINANCIAL MEASURES

(UNAUDITED)

(Dollars in thousands)

 

     For the Three Months Ended     For the Nine Months Ended  
     March 31,
2014
     March 31,
2013
    March 31,
2014
    March 31,
2013
 

Net income

   $ 4,246       $ 1,536      $ 10,016      $ 7,834   

Interest expense

     187         136        547        390   

Interest income

     —           (48     (2     (99

Provision for income taxes

     2,014         832        4,857        831   

Depreciation and amortization

     2,270         1,564        5,910        3,036   

Restructuring/impairment charges

     —           —          188        —     

Gross profit effect of capitalized profit in inventory from acquisition

     148         —          256        566   
  

 

 

    

 

 

   

 

 

   

 

 

 

Adjusted EBITDA

   $ 8,865       $ 4,020      $ 21,772      $ 12,558   
  

 

 

    

 

 

   

 

 

   

 

 

 


SPARTON CORPORATION AND SUBSIDIARIES

RECONCILIATON OF NON-GAAP FINANCIAL MEASURES

(UNAUDITED)

(Dollars in thousands)

 

     For the Three Months Ended March 31, 2014  
     Medical      CS      DSS      Other
Unallocated
     Total  

Gross profit

   $ 5,332       $ 2,488       $ 8,606       $ —         $ 16,426   

Gross profit effect of capitalized profit in inventory from acquisition

     —           67         81         —           148   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Adjusted gross profit

   $ 5,332       $ 2,555       $ 8,687       $ —         $ 16,574   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

     For the Three Months Ended March 31, 2013  
     Medical      CS      DSS      Other
Unallocated
     Total  

Gross profit

   $ 5,339       $ 1,890       $ 2,896       $ —         $ 10,125   
     —           —           —           —           —     
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Adjusted gross profit

   $ 5,339       $ 1,890       $ 2,896       $ —         $ 10,125   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

     For the Nine Months Ended March 31, 2014  
     Medical      CS      DSS      Other
Unallocated
     Total  

Gross profit

   $ 19,134       $ 6,300       $ 18,163       $ —         $ 43,597   

Gross profit effect of capitalized profit in inventory from acquisition

             67         189         —           256   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Adjusted gross profit

   $ 19,134       $ 6,367       $ 18,352       $ —         $ 43,853   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

     For the Nine Months Ended March 31, 2013  
     Medical      CS      DSS      Other
Unallocated
     Total  

Gross profit

   $ 13,877       $ 4,414       $ 11,929       $ —         $ 30,220   

Gross profit effect of capitalized profit in inventory from acquisition

     566         —           —           —           566   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Adjusted gross profit

   $ 14,443       $ 4,414       $ 11,929       $ —         $ 30,786   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 


SPARTON CORPORATION AND SUBSIDIARIES

RECONCILIATON OF NON-GAAP FINANCIAL MEASURES

(UNAUDITED)

(Dollars in thousands)

 

     For the Three Months Ended March 31, 2014  
     Medical      CS      DSS      Other
Unallocated
    Total  

Operating income (loss)

   $ 2,468       $ 946       $ 6,112       $ (3,203   $ 6,323   

Gross profit effect of capitalized profit in inventory from acquisition

     —           67         81         —          148   
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

Adjusted operating income (loss)

   $ 2,468       $ 1,013       $ 6,193       $ (3,203   $ 6,471   
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

Depreciation/amortization

   $ 1,164       $ 666       $ 341       $ 99      $ 2,270   
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

 

     For the Three Months Ended March 31, 2013  
     Medical      CS      DSS      Other
Unallocated
    Total  

Operating income (loss)

   $ 2,483       $ 1,203       $ 1,351       $ (2,687   $ 2,350   
     —           —           —           —          —     
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

Adjusted operating income (loss)

   $ 2,483       $ 1,203       $ 1,351       $ (2,687   $ 2,350   
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

Depreciation/amortization

   $ 1,182       $ 148       $ 157       $ 77      $ 1,564   
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

 

     For the Nine Months Ended March 31, 2014  
     Medical      CS      DSS      Other
Unallocated
    Total  

Operating income (loss)

   $ 10,072       $ 2,850       $ 10,986       $ (8,951   $ 14,957   

Gross profit effect of capitalized profit in inventory from acquisition

     —           67         189         —          256   

Restructuring expense

     —           188         —           —          188   
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

Adjusted operating income (loss)

   $ 10,072       $ 3,105       $ 11,175       $ (8,951   $ 15,401   
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

Depreciation/amortization

   $ 3,626       $ 1,088       $ 905       $ 291      $ 5,910   
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

 

     For the Nine Months Ended March 31, 2013  
     Medical      CS      DSS      Other
Unallocated
    Total  

Operating income (loss)

   $ 6,908       $ 2,366       $ 7,506       $ (8,099   $ 8,681   

Gross profit effect of capitalized profit in inventory from acquisition

     566         —           —           —          566   
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

Adjusted operating income (loss)

   $ 7,474       $ 2,366       $ 7,506       $ (8,099   $ 9,247   
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

Depreciation/amortization

   $ 1,989       $ 439       $ 454       $ 154      $ 3,036